Use of sildenafil and other phosphodiesterase type 5 inhibitors among pregnant women in Scandinavia

ConclusionsFew women used PDE5 inhibitors in outpatient settings before or during pregnancy in the Scandinavian countries in the last decades. Only a small proportion had a diagnosis for pulmonary arterial hypertension, suggesting off-label use in the remaining users. Use was predominantly in mothers over age 35  years. The safety of fetal exposure to sildenafil and other PDE5 inhibitors in pregnancy has not been established. As maternal age continues to increase and additional uses of PDE5 inhibitors are investigated, the safety of these drugs in pregnancy should be thoroughly evaluated.

Source: Acta Obstetricia et Gynecologica Scandinavica - August 29, 2021 Category: OBGYN Authors: Carolyn E. Cesta, Silvia Segovia Chac ón, Anders Engeland, Anne Broe, Per Damkier, Kari Furu, Helle Kieler, Pär Karlsson Tags: ORIGINAL RESEARCH ARTICLE Source Type: research